Does the media favor ABCL or CABA?

In the previous week, AbCellera Biologics had 27 more articles in the media than Cabaletta Bio. MarketBeat recorded 33 mentions for AbCellera Biologics and 6 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.40 beat AbCellera Biologics' score of 0.68 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 12 Very Positive mention(s) 4 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Cabaletta Bio 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMCR or CABA more profitable?

Cabaletta Bio has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Immunocore -4.20% -4.54% -1.66% Cabaletta Bio N/A -153.30% -108.14%

Does the media prefer IMCR or CABA?

In the previous week, Immunocore had 9 more articles in the media than Cabaletta Bio. MarketBeat recorded 15 mentions for Immunocore and 6 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.40 beat Immunocore's score of 0.73 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CABA or SNDX?

In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than Cabaletta Bio. MarketBeat recorded 9 mentions for Syndax Pharmaceuticals and 6 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.40 beat Syndax Pharmaceuticals' score of -0.22 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CABA or TSHA more profitable?

Taysha Gene Therapies' return on equity of -56.19% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -153.30% -108.14% Taysha Gene Therapies N/A -56.19% -41.84%

Does the media refer more to CABA or TSHA?

In the previous week, Taysha Gene Therapies had 10 more articles in the media than Cabaletta Bio. MarketBeat recorded 16 mentions for Taysha Gene Therapies and 6 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.40 beat Taysha Gene Therapies' score of 0.05 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 1 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, AAPG or CABA?

Cabaletta Bio has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 21.44 -$177.71M N/A N/A Cabaletta Bio N/A N/A -$167.86M -$1.96 N/A

Is AAPG or CABA more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Cabaletta Bio N/A -153.30% -108.14%

Does the media prefer AAPG or CABA?

In the previous week, Cabaletta Bio had 2 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 6 mentions for Cabaletta Bio and 4 mentions for Ascentage Pharma Group International. Cabaletta Bio's average media sentiment score of 1.40 beat Ascentage Pharma Group International's score of 0.20 indicating that Cabaletta Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Cabaletta Bio 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cabaletta Bio (CABA) Competitors

$2.75 +0.04 (+1.48%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.78 +0.03 (+1.09%)

As of 08/14/2026 07:58 PM Eastern

Compare

CABA vs. ABCL, IMCR, SNDX, TSHA, and AAPG

Should you buy Cabaletta Bio stock or one of its competitors? Cabaletta Bio's main competitors and comparable companies include AbCellera Biologics (ABCL), Immunocore (IMCR), Syndax Pharmaceuticals (SNDX), Taysha Gene Therapies (TSHA), and Ascentage Pharma Group International (AAPG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cabaletta Bio compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Cabaletta Bio (NASDAQ:CABA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

AbCellera Biologics presently has a consensus price target of $12.83, suggesting a potential upside of 12.77%. Cabaletta Bio has a consensus price target of $15.33, suggesting a potential upside of 457.58%. Given Cabaletta Bio's higher possible upside, analysts clearly believe Cabaletta Bio is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, AbCellera Biologics had 27 more articles in the media than Cabaletta Bio. MarketBeat recorded 33 mentions for AbCellera Biologics and 6 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.40 beat AbCellera Biologics' score of 0.68 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	12 Very Positive mention(s)	4 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Cabaletta Bio	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.3, meaning that its stock price is 230% more volatile than the broader market.

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cabaletta Bio has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Cabaletta Bio	N/A	-153.30%	-108.14%

AbCellera Biologics has higher revenue and earnings than Cabaletta Bio. AbCellera Biologics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	46.44	-$146.41M	-$0.54	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

Summary

AbCellera Biologics beats Cabaletta Bio on 10 of the 16 factors compared between the two stocks.

How does Cabaletta Bio compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Cabaletta Bio has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Cabaletta Bio	N/A	-153.30%	-108.14%

84.5% of Immunocore shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Immunocore has higher revenue and earnings than Cabaletta Bio. Immunocore is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.35	-$35.51M	-$0.37	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.3, indicating that its stock price is 230% more volatile than the broader market.

Immunocore presently has a consensus price target of $57.29, indicating a potential upside of 67.45%. Cabaletta Bio has a consensus price target of $15.33, indicating a potential upside of 457.58%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Immunocore had 9 more articles in the media than Cabaletta Bio. MarketBeat recorded 15 mentions for Immunocore and 6 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.40 beat Immunocore's score of 0.73 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunocore beats Cabaletta Bio on 9 of the 15 factors compared between the two stocks.

How does Cabaletta Bio compare to Syndax Pharmaceuticals?

Cabaletta Bio (NASDAQ:CABA) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Cabaletta Bio has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Syndax Pharmaceuticals	$172.35M	10.20	-$285.42M	-$2.51	N/A

In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than Cabaletta Bio. MarketBeat recorded 9 mentions for Syndax Pharmaceuticals and 6 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.40 beat Syndax Pharmaceuticals' score of -0.22 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cabaletta Bio has a beta of 3.3, indicating that its share price is 230% more volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Cabaletta Bio currently has a consensus price target of $15.33, suggesting a potential upside of 457.58%. Syndax Pharmaceuticals has a consensus price target of $41.91, suggesting a potential upside of 111.24%. Given Cabaletta Bio's higher probable upside, equities research analysts plainly believe Cabaletta Bio is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Cabaletta Bio has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Cabaletta Bio's return on equity of -153.30% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-153.30%	-108.14%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Summary

Cabaletta Bio beats Syndax Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Cabaletta Bio compare to Taysha Gene Therapies?

Cabaletta Bio (NASDAQ:CABA) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Cabaletta Bio has a beta of 3.3, indicating that its share price is 230% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Taysha Gene Therapies' return on equity of -56.19% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-153.30%	-108.14%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Taysha Gene Therapies has higher revenue and earnings than Cabaletta Bio. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Taysha Gene Therapies	$9.77M	198.43	-$109M	-$0.38	N/A

77.7% of Taysha Gene Therapies shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Taysha Gene Therapies had 10 more articles in the media than Cabaletta Bio. MarketBeat recorded 16 mentions for Taysha Gene Therapies and 6 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 1.40 beat Taysha Gene Therapies' score of 0.05 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	1 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cabaletta Bio presently has a consensus target price of $15.33, suggesting a potential upside of 457.58%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 114.61%. Given Cabaletta Bio's higher probable upside, research analysts clearly believe Cabaletta Bio is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Taysha Gene Therapies beats Cabaletta Bio on 10 of the 15 factors compared between the two stocks.

How does Cabaletta Bio compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Ascentage Pharma Group International has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.3, meaning that its share price is 230% more volatile than the broader market.

Ascentage Pharma Group International's return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Cabaletta Bio	N/A	-153.30%	-108.14%

Ascentage Pharma Group International currently has a consensus price target of $46.43, suggesting a potential upside of 146.38%. Cabaletta Bio has a consensus price target of $15.33, suggesting a potential upside of 457.58%. Given Cabaletta Bio's higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Cabaletta Bio has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	21.44	-$177.71M	N/A	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

In the previous week, Cabaletta Bio had 2 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 6 mentions for Cabaletta Bio and 4 mentions for Ascentage Pharma Group International. Cabaletta Bio's average media sentiment score of 1.40 beat Ascentage Pharma Group International's score of 0.20 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cabaletta Bio	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascentage Pharma Group International beats Cabaletta Bio on 6 of the 11 factors compared between the two stocks.

Get Cabaletta Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CABA vs. The Competition

Export

Metric	Cabaletta Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$441.88M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.70%	2.57%	10.45%
P/E Ratio	-1.75	10.67	269.06	25.28
Price / Sales	N/A	1,275.04	592.96	87.71
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	2.37	16.78	12.91	6.24
Net Income	-$167.86M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-1.43%	1.74%	1.12%	1.07%
1 Month Performance	3.00%	1.60%	1.79%	1.03%
1 Year Performance	66.67%	56.43%	67.69%	20.77%

Cabaletta Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CABA Cabaletta Bio	2.7921 of 5 stars	$2.75 +1.5%	$15.33 +457.6%	+66.7%	$441.88M	N/A	N/A	50	News Coverage Positive News Earnings Report Analyst Forecast
ABCL AbCellera Biologics	2.013 of 5 stars	$5.83 +2.1%	$8.00 +37.2%	+152.9%	$1.74B	$75.13M	N/A	500	Analyst Forecast
IMCR Immunocore	3.7588 of 5 stars	$32.43 -4.1%	$56.29 +73.6%	+3.5%	$1.72B	$400.02M	N/A	320	Trending News Earnings Report Analyst Revision
SNDX Syndax Pharmaceuticals	2.1214 of 5 stars	$19.24 +1.0%	$42.55 +121.1%	+34.7%	$1.69B	$172.35M	N/A	110	Positive News Analyst Forecast
TSHA Taysha Gene Therapies	2.6161 of 5 stars	$5.78 -1.4%	$12.77 +120.9%	+102.4%	$1.68B	$9.77M	N/A	180	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CABA) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cabaletta Bio (CABA) Competitors

CABA vs. ABCL, IMCR, SNDX, TSHA, and AAPG

How does Cabaletta Bio compare to AbCellera Biologics?

Summary

How does Cabaletta Bio compare to Immunocore?

Summary

How does Cabaletta Bio compare to Syndax Pharmaceuticals?

Summary

How does Cabaletta Bio compare to Taysha Gene Therapies?

Summary

How does Cabaletta Bio compare to Ascentage Pharma Group International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cabaletta Bio (CABA) Competitors

CABA vs. ABCL, IMCR, SNDX, TSHA, and AAPG

How does Cabaletta Bio compare to AbCellera Biologics?

Do analysts rate ABCL or CABA?

Does the media favor ABCL or CABA?

Which has more volatility & risk, ABCL or CABA?

Do insiders and institutionals have more ownership in ABCL or CABA?

Is ABCL or CABA more profitable?

Which has better valuation & earnings, ABCL or CABA?

Summary

How does Cabaletta Bio compare to Immunocore?

Is IMCR or CABA more profitable?

Do institutionals and insiders have more ownership in IMCR or CABA?

Which has higher valuation & earnings, IMCR or CABA?

Which has more risk and volatility, IMCR or CABA?

Do analysts prefer IMCR or CABA?

Does the media prefer IMCR or CABA?

Summary

How does Cabaletta Bio compare to Syndax Pharmaceuticals?

Which has better earnings and valuation, CABA or SNDX?

Does the media prefer CABA or SNDX?

Which has more risk & volatility, CABA or SNDX?

Do analysts recommend CABA or SNDX?

Is CABA or SNDX more profitable?

Summary

How does Cabaletta Bio compare to Taysha Gene Therapies?

Which has more risk & volatility, CABA or TSHA?

Is CABA or TSHA more profitable?

Which has higher valuation and earnings, CABA or TSHA?

Do insiders and institutionals hold more shares of CABA or TSHA?

Does the media refer more to CABA or TSHA?

Do analysts recommend CABA or TSHA?

Summary

How does Cabaletta Bio compare to Ascentage Pharma Group International?

Which has more volatility & risk, AAPG or CABA?

Is AAPG or CABA more profitable?

Do analysts recommend AAPG or CABA?

Which has preferable earnings & valuation, AAPG or CABA?

Does the media prefer AAPG or CABA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools